Skip to main content

Advertisement

SpringerLink
Log in

Drug-Induced Liver Injury in Children

  • Drug-Induced Liver Injury (NP Chalasani and MS Ghabril, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Drug-induced liver injury (DILI) is relatively rare among children but can cause substantial morbidity and mortality. Here, we summarize the literature on pediatric DILI including a focus on commonly used classes of drugs.

Recent Findings

The incidence of pediatric DILI remains poorly defined. Antimicrobials and antiepileptic medications are the most commonly reported causes of pediatric idiosyncratic DILI in the US DILI network (DILIN) experience. DILI among children being treated for cancer appears to be underreported, and recent literature clearly implicates newer classes of agents such as tumor necrosis factor-α inhibitors as potentially hepatotoxic. Many drugs trigger signature patterns of DILI; autoimmune hepatitis secondary to minocycline is an example.

Summary

DILI should be suspected whenever a child presents with evidence of liver injury. Familiarity with established patterns of DILI secondary to specific agents can facilitate recognition of cases. Active reporting of cases by clinicians to registries such as US DILIN remains critical to a continuing understanding of the causes and risk factors of DILI among children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–66. https://doi.org/10.1001/jama.296.15.1858.

    Article  CAS  PubMed  Google Scholar 

  2. Budnitz DS, Salis S. Preventing medication overdoses in young children: an opportunity for harm elimination. Pediatrics. 2011;127(6):e1597–9. https://doi.org/10.1542/peds.2011-0926.

    Article  PubMed  Google Scholar 

  3. Regev A. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. Clin Liver Dis. 2013;17(4):749–67, xi. https://doi.org/10.1016/j.cld.2013.07.014.

    Article  PubMed  Google Scholar 

  4. Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013;17(4):575–86. https://doi.org/10.1016/j.cld.2013.07.001. viii

    Article  PubMed  Google Scholar 

  5. •• Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52 e7. https://doi.org/10.1053/j.gastro.2015.03.006. Most recent review of data from the US Drug-Induced Liver Injury Network prospective study.

    Article  PubMed  PubMed Central  Google Scholar 

  6. • Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5. https://doi.org/10.1053/jhep.2002.34857. Population-based study of DILI from France.

    Article  PubMed  Google Scholar 

  7. • Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25, 25 e1–3; quiz e19–20. https://doi.org/10.1053/j.gastro.2013.02.006. Population-based study of DILI from Iceland.

    Article  Google Scholar 

  8. CDC. Health, United States, 2016. https://www.cdc.gov/nchs/hus/contents2016.htm#079. Accessed July 31st, 2017 2017.

  9. Alonso RHSaEM. Acute liver failure in children. In: Frederick Suchy, Ronald Sokol, William Balistreri, editor. Liver disease in children. 4 ed.: Cambridge University Press; 2014.

  10. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure. 2010;19(3):140–6. https://doi.org/10.1016/j.seizure.2010.01.002.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Star K, Edwards IR, Choonara I. Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase. PLoS One. 2014;9(10):e108970. https://doi.org/10.1371/journal.pone.0108970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. •• LiverTox. https://livertox.nlm.nih.gov//. LiverTox is an online, searchable database providing up-to-date information on the characteristics of DILI related to prescription and nonprescription medications, herbals, and dietary supplements.

  13. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117–26. https://doi.org/10.1002/hep.23577.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem. 2012;58(5):854–68. https://doi.org/10.1373/clinchem.2011.177741.

    Article  CAS  PubMed  Google Scholar 

  15. Adeli K, Higgins V, Nieuwesteeg M, Raizman JE, Chen Y, Wong SL, et al. Complex reference values for endocrine and special chemistry biomarkers across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. Clin Chem. 2015;61(8):1063–74. https://doi.org/10.1373/clinchem.2015.240523.

    Article  CAS  PubMed  Google Scholar 

  16. • Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53(2):182–9. https://doi.org/10.1097/MPG.0b013e31821d6cfd. The initial review of pediatric data from the US Drug-Induced Liver Injury Network prospective study.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. DiPaola F, Molleston JP, Gu S, Cirulli ET, Chalasani N, Barnhart H, et al. Minocycline and anti-epileptics are the leading causes of DILI in children: a report from the US Drug-Induced Liver Injury Network. Washington, DC: The Liver Meeting, American Association for the Study of Liver diseases; 2017.

    Google Scholar 

  18. Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60(9):1308–16. https://doi.org/10.1093/cid/civ076.

    Article  PubMed  Google Scholar 

  19. Olson SC, Smith S, Weissman SJ, Kronman MP. Adverse events in pediatric patients receiving long-term outpatient antimicrobials. J Pediatric Infect Dis Soc. 2015;4(2):119–25. https://doi.org/10.1093/jpids/piu037.

    Article  PubMed  Google Scholar 

  20. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–76. https://doi.org/10.1007/s10620-011-1611-4.

    Article  CAS  PubMed  Google Scholar 

  21. Kumar A, Sood V, Khanna R, Verma SK, Mehra N, Rawat D, et al. Clinical spectrum and outcome of pediatric drug induced liver injury. Indian J Pediatr. 2017; https://doi.org/10.1007/s12098-017-2570-3.

    Article  Google Scholar 

  22. Devarbhavi H, Patil M, Reddy VV, Singh R, Joseph T, Ganga D. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int. 2017;38:1322–9. https://doi.org/10.1111/liv.13662.

    Article  PubMed  Google Scholar 

  23. Yang LX, Liu CY, Zhang LL, Lai LL, Fang M, Zhang C. Clinical characteristics of patients with drug-induced liver injury. Chin Med J. 2017;130(2):160–4. https://doi.org/10.4103/0366-6999.197995.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Zhu Y, Li YG, Wang JB, Liu SH, Wang LF, Zhao YL, et al. Causes, features, and outcomes of drug-induced liver injury in 69 children from China. Gut Liver. 2015;9(4):525–33. https://doi.org/10.5009/gnl14184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in children receiving isoniazid therapy for latent tuberculosis infection. J Pediatric Infect Dis Soc. 2014;3(3):221–7. https://doi.org/10.1093/jpids/pit089.

    Article  PubMed  Google Scholar 

  26. Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, et al. Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol. 2015;13(9):1676–82 e1. https://doi.org/10.1016/j.cgh.2015.02.024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13(2):369–76.e3. https://doi.org/10.1016/j.cgh.2014.07.054.

    Article  CAS  PubMed  Google Scholar 

  28. Karthik SV, Casson D. Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience. J Clin Gastroenterol. 2005;39(8):743–4.

    Article  Google Scholar 

  29. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci. 1979;24(5):385–96.

    Article  CAS  Google Scholar 

  30. Ginsburg CM. A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia. Pediatr Infect Dis. 1986;5(1):151–3.

    Article  CAS  Google Scholar 

  31. Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis. 2002;34(1):50–4. https://doi.org/10.1086/338047.

    Article  CAS  PubMed  Google Scholar 

  32. Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. J Pediatr. 1976;89(5):835–8.

    Article  CAS  Google Scholar 

  33. • Chalasani N, Reddy KRK, Fontana RJ, Barnhart H, Gu J, Hayashi PH, et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians. Am J Gastroenterol. 2017;112(9):1382–8. https://doi.org/10.1038/ajg.2017.215. Analysis from US DILIN demonstrating key differences in etiologies and outcomes of DILI by race.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol. 2010;70(5):721–8. https://doi.org/10.1111/j.1365-2125.2010.03754.x.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 2010;52(5):1791–6. https://doi.org/10.1002/hep.23891.

    Article  CAS  PubMed  Google Scholar 

  36. Li S, Guo J, Ying Z, Chen S, Yang L, Chen K, et al. Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Hepatology. 2015;61(5):1730–9. https://doi.org/10.1002/hep.27712.

    Article  CAS  PubMed  Google Scholar 

  37. Brown TS, Appel JE, Kasteler JS, Callen JP. Hypersensitivity reaction in a child due to lamotrigine. Pediatr Dermatol. 1999;16(1):46–9.

    Article  CAS  Google Scholar 

  38. Bhayana H, Appasani S, Thapa BR, Das A, Singh K. Lamotrigine-induced vanishing bile duct syndrome in a child. J Pediatr Gastroenterol Nutr. 2012;55(6):e147–8. https://doi.org/10.1097/MPG.0b013e31823c2500.

    Article  PubMed  Google Scholar 

  39. Matsukura H, Suzuki Y. A case of hepatitis associated with carbamazepine therapy. Eur J Pediatr. 1988;147(6):666.

    Article  CAS  Google Scholar 

  40. Hadzic N, Portmann B, Davies ET, Mowat AP, Mieli-Vergani G. Acute liver failure induced by carbamazepine. Arch Dis Child. 1990;65(3):315–7.

    Article  CAS  Google Scholar 

  41. Horneff G, Lenard HG, Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics. 1992;23(5):272–5. https://doi.org/10.1055/s-2008-1071357.

    Article  CAS  PubMed  Google Scholar 

  42. Bellman B, Schachner LA, Pravder L, McFalls S, Shapiro B. Carbamazepine hypersensitivity. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1405–6. https://doi.org/10.1097/00004583-199511000-00005.

    Article  CAS  PubMed  Google Scholar 

  43. Troost RJ, Oranje AP, Lijnen RL, Benner R, Prens EP. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol. 1996;13(4):316–20.

    Article  CAS  Google Scholar 

  44. Wadhawan M, Tyagi P, Malhotra V, Sakhuja P, Puri AS. Reversible cholestatic hepatitis due to carbamazepine in an adolescent. Indian J Gastroenterol. 2005;24(4):172–3.

    PubMed  Google Scholar 

  45. Aouam K, Ben Romdhane F, Loussaief C, Salem R, Toumi A, Belhadjali H, et al. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity between carbamazepine and lamotrigine. J Clin Pharmacol. 2009;49(12):1488–91. https://doi.org/10.1177/0091270009344985.

    Article  CAS  PubMed  Google Scholar 

  46. Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology. 2011;54(4):1344–50. https://doi.org/10.1002/hep.24527.

    Article  CAS  PubMed  Google Scholar 

  47. Buyuktiryaki AB, Bezirganoglu H, Sahiner UM, Yavuz ST, Tuncer A, Kara A, et al. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. Aust J Dermatol. 2012;53(4):274–7. https://doi.org/10.1111/j.1440-0960.2012.00887.x.

    Article  Google Scholar 

  48. Teng P, Tan B. Carbamazepine-induced DRESS syndrome in a child: rapid response to pulsed corticosteroids. Dermatol Online J. 2013;19(5):18170.

    PubMed  Google Scholar 

  49. Arnon R, DeVivo D, Defelice AR, Kazlow PG. Acute hepatic failure in a child treated with lamotrigine. Pediatr Neurol. 1998;18(3):251–2.

    Article  CAS  Google Scholar 

  50. Zucker P, Daum F, Cohen MI. Fatal carbamazepine hepatitis. J Pediatr. 1977;91(4):667–8.

    Article  CAS  Google Scholar 

  51. Luke DR, Rocci ML Jr, Schaible DH, Ferguson RK. Acute hepatotoxicity after excessively high doses of carbamazepine on two occasions. Pharmacotherapy. 1986;6(3):108–11.

    Article  CAS  Google Scholar 

  52. Viani F, Claris-Appiani A, Rossi LN, Giani M, Romeo A. Severe hepatorenal failure in a child receiving carbamazepine and erythromycin. Eur J Pediatr. 1992;151(9):715.

    Article  CAS  Google Scholar 

  53. Haase MR. Carbamazepine-induced hepatorenal failure in a child. Pharmacotherapy. 1999;19(5):667–71.

    Article  CAS  Google Scholar 

  54. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391–9.

    CAS  PubMed  Google Scholar 

  55. Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006;148(6):831–4. https://doi.org/10.1016/j.jpeds.2006.01.035.

    Article  PubMed  Google Scholar 

  56. Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila). 2007;45(1):51–5.

    Article  CAS  Google Scholar 

  57. Erdogan A, Ozcay F, Piskin E, Karaman MG, Bilezikci B, Calik M, et al. Idiosyncratic liver failure probably associated with atomoxetine: a case report. J Child Adolesc Psychopharmacol. 2011;21(3):295–7. https://doi.org/10.1089/cap.2010.0101.

    Article  PubMed  Google Scholar 

  58. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33(1):50–67. https://doi.org/10.1053/j.seminoncol.2005.11.002.

    Article  CAS  PubMed  Google Scholar 

  59. McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut. 2008;57(7):987–1003. https://doi.org/10.1136/gut.2007.131136.

    Article  CAS  PubMed  Google Scholar 

  60. Castellino S, Muir A, Shah A, Shope S, McMullen K, Ruble K, et al. Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2010;54(5):663–9. https://doi.org/10.1002/pbc.22265.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Ebbesen MS, Nygaard U, Rosthoj S, Sorensen D, Nersting J, Vettenranta K, et al. Hepatotoxicity during maintenance therapy and prognosis in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2017;39(3):161–6. https://doi.org/10.1097/mph.0000000000000733.

    Article  CAS  PubMed  Google Scholar 

  62. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554–63. https://doi.org/10.1097/MPH.0b013e3181e6f003.

    Article  CAS  PubMed  Google Scholar 

  63. Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–53. https://doi.org/10.3109/10428194.2011.596963.

    Article  CAS  PubMed  Google Scholar 

  64. Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(4):748–57. https://doi.org/10.3109/10428194.2015.1101098.

    Article  CAS  PubMed  Google Scholar 

  65. Ricart AD. Drug-induced liver injury in Oncology. Ann Oncol. 2017;28(8):2013–20. https://doi.org/10.1093/annonc/mdx158.

    Article  CAS  PubMed  Google Scholar 

  66. Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123(1):100–2.

    Article  Google Scholar 

  67. Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol. 2004;75(4):225–30. https://doi.org/10.1002/ajh.20024.

    Article  PubMed  Google Scholar 

  68. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology. 2006;44(1):7–14. https://doi.org/10.1002/hep.21258.

    Article  PubMed  Google Scholar 

  69. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102(7):1518–27. https://doi.org/10.1111/j.1572-0241.2007.01187.x.

    Article  CAS  PubMed  Google Scholar 

  70. Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22(9):775–82. https://doi.org/10.1111/j.1365-2036.2005.02636.x.

    Article  CAS  PubMed  Google Scholar 

  71. Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13(9):1106–14. https://doi.org/10.1002/ibd.20160.

    Article  PubMed  Google Scholar 

  72. Moran GW, Dubeau MF, Kaplan GG, Yang H, Eksteen B, Ghosh S, et al. Clinical predictors of thiopurine-related adverse events in Crohn’s disease. World J Gastroenterol. 2015;21(25):7795–804. https://doi.org/10.3748/wjg.v21.i25.7795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Bjornsson ES, Gu J, Kleiner DE, Chalasani N, Hayashi PH, Hoofnagle JH, et al. Azathioprine and 6-mercaptopurine-induced liver injury: clinical features and outcomes. J Clin Gastroenterol. 2017;51(1):63–9. https://doi.org/10.1097/MCG.0000000000000568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Kuriyama M, Kato J, Suzuki H, Akita M, Hiraoka S, Okada H, et al. Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis. Dig Endosc. 2010;22(4):289–96. https://doi.org/10.1111/j.1443-1661.2010.01009.x.

    Article  PubMed  Google Scholar 

  75. Knowles SR, Gupta AK, Shear NH, Sauder D. Azathioprine hypersensitivity-like reactions—a case report and a review of the literature. Clin Exp Dermatol. 1995;20(4):353–6.

    Article  CAS  Google Scholar 

  76. Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(1):224–33. https://doi.org/10.1097/MIB.0000000000000589.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol. 2007;102(12):2804–12. https://doi.org/10.1111/j.1572-0241.2007.01474.x. quiz 3, 13

    Article  CAS  PubMed  Google Scholar 

  78. Haisma SM, Lijftogt T, Kindermann A, Damen G, de Ridder L, Escher JC, et al. Methotrexate for maintaining remission in paediatric Crohn’s patients with prior failure or intolerance to thiopurines: a multicenter cohort study. J Crohns Colitis. 2015;9(4):305–11. https://doi.org/10.1093/ecco-jcc/jjv031.

    Article  PubMed  Google Scholar 

  79. Sunseri W, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20(8):1341–5. https://doi.org/10.1097/MIB.0000000000000102.

    Article  PubMed  Google Scholar 

  80. Turner D, Doveh E, Cohen A, Wilson ML, Grossman AB, Rosh JR, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease: a multicentre propensity score study. Gut. 2015;64(12):1898–904. https://doi.org/10.1136/gutjnl-2014-307964.

    Article  CAS  PubMed  Google Scholar 

  81. Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4(3):221–56. https://doi.org/10.1016/j.crohns.2009.12.001.

    Article  CAS  PubMed  Google Scholar 

  82. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–64 e3. https://doi.org/10.1016/j.cgh.2012.12.025.

    Article  CAS  PubMed  Google Scholar 

  83. French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-alpha agents. Drug Saf. 2016;39(3):199–208. https://doi.org/10.1007/s40264-015-0366-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Mostamand S, Schroeder S, Schenkein J, Miloh T. Infliximab-associated immunomediated hepatitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;63(1):94–7. https://doi.org/10.1097/MPG.0000000000001137.

    Article  CAS  PubMed  Google Scholar 

  85. Ricciuto A, Kamath BM, Walters TD, Frost K, Carman N, Church PC, et al. New onset autoimmune hepatitis during anti-tumor necrosis factor-alpha treatment in children. J Pediatr. 2018;194:128–35 e1. https://doi.org/10.1016/j.jpeds.2017.10.071.

    Article  CAS  PubMed  Google Scholar 

  86. Seeff LB, Bonkovsky HL, Navarro VJ, Wang G. Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology. 2015;148(3):517–32.e3. https://doi.org/10.1053/j.gastro.2014.12.004.

    Article  CAS  PubMed  Google Scholar 

  87. Lawrenson JA, Walls T, Day AS. Echinacea-induced acute liver failure in a child. J Paediatr Child Health. 2014;50(10):841. https://doi.org/10.1111/jpc.12726.

    Article  PubMed  Google Scholar 

  88. • Navarro VJ, Khan I, Bjornsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363–73. https://doi.org/10.1002/hep.28813. Review of etiology and diagnosis of herbal and supplement DILI that emphasizes the need to clarify purity and safety.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, USA

    Frank DiPaola

  2. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, 705 Riley Hospital Drive, ROC 4210, Indianapolis, IN, 46202, USA

    Jean P. Molleston

Authors
  1. Frank DiPaola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean P. Molleston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean P. Molleston.

Ethics declarations

Conflict of Interest

Frank DiPaola reports a grant from NIH DILIN. Jean Molleston reports grants from Gilead, Shire, Abbvie, CF Foundation, and NIH DILIN Network, and consulting for Lilly, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Drug-Induced Liver Injury

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DiPaola, F., Molleston, J.P. Drug-Induced Liver Injury in Children. Curr Hepatology Rep 17, 283–291 (2018). https://doi.org/10.1007/s11901-018-0413-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-018-0413-y

Keywords

Search

Navigation